{"nctId":"NCT04625972","briefTitle":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","startDateStruct":{"date":"2020-12-02","type":"ACTUAL"},"conditions":["COVID-19"],"count":1131,"armGroups":[{"label":"AZD7442","type":"EXPERIMENTAL","interventionNames":["Drug: AZD7442"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"AZD7442","otherNames":["A combination of 2 mAbs (AZD8895 and AZD1061)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. â‰¥ 18 years of age at the time of signing the informed consent\n2. Adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed SARS-COV-2 infection, symptomatic or asymptomatic\n3. Participants must not have had COVID-19 symptoms within 10 days of dosing\n4. Negative result from point of care SARS-CoV-2 serology test at screening\n5. Contraception used by women of childbearing potential, condom by men\n6. Able to understand and comply with study requirements/procedures based on the assessment of the investigator\n\nExclusion Criteria:\n\n1. History of laboratory-confirmed SARS-CoV-2 infection or SARS-CoV-2 seropositivity at screening.\n2. History of infection with severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).\n3. Known history of allergy or reaction to any component of the study drug formulation.\n4. Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mAb.\n5. Any prior receipt of investigational or licensed vaccine or other mAb/biologic indicated for the prevention of SARS-CoV-2 or COVID-19 or expected receipt during the period of study follow up.\n6. Clinically significant bleeding disorder or prior history of significant bleeding or bruising following IM injections or venipuncture.\n7. Any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data.\n8. Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study.\n9. Currently pregnant or breast feeding.\n10. Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to randomization.\n11. Employees of the Sponsor involved in planning, executing, supervising, or reviewing the AZD7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.\n12. In nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With First Case of SARS-CoV-2 RT-PCR Positive Symptomatic Illness","description":"To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of COVID-19","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"PRIMARY","title":"AEs, SAEs, MAAEs, and AESIs Post Dose of IMP","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"345","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Participants Who Have a Post-treatment Response (Negative at Baseline to Positive at Any Time Post-baseline) for SARSCoV- 2 Nucleocapsid Antibodies","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of COVID-19-related Death Occurring After Dosing With IMP","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of All-cause Mortality Occurring After Dosing With IMP","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum AZD7442 Concentrations, PK Parameters","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.028","spread":"110.166"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.718","spread":"72.721"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.420","spread":"75.160"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.183","spread":"81.706"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.975","spread":"79.694"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.696","spread":"63.725"}]}]}]},{"type":"SECONDARY","title":"Incidence of ADA to AZD7442 in Serum","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":749},"commonTop":["Covid-19","Headache","Cough","Fatigue","Rhinorrhoea"]}}}